Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens
- PMID: 21841504
- DOI: 10.1097/JTO.0b013e318227142d
Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens
Abstract
Background: There is growing evidence that lung adenocarcinoma and squamous cell carcinoma (SQCC) have distinct oncogenic mutations and divergent therapeutic responses, which is driving the heightened emphasis on accurate pathologic subtyping of non-small cell lung carcinoma (NSCLC). The relative feasibility and accuracy of NSCLC subtyping by small biopsy versus cytology is not well established, particularly in current practice where immunohistochemistry (IHC) is becoming routinely used to aid in this distinction.
Methods: Concurrent biopsy and cytology specimens obtained during a single procedure and diagnosed as NSCLC during a 2-year period (n = 101) were reviewed. Concordance of diagnoses in the two methods was assessed. Accuracy was determined based on subsequent resection or autopsy diagnosis (n = 21) or IHC for thyroid transcription factor 1 and p63 on a subset of cases (n = 43).
Results: The distribution of definitive versus favored versus unclassified categories (reflecting the degree of diagnostic certainty) was similar for biopsy (71% versus 23% versus 6%, respectively) and cytology (69% versus 19% versus 12%, respectively), p = 0.29. When results from paired specimens were combined, the rate of definitive diagnoses by at least one method was increased to 84% and the unclassified rate was decreased to 4%. NSCLC subtype concordance between biopsy and cytology was 93%. Kappa coefficient (95% confidence interval) for agreement between methods was 0.88 (0.60-0.89) for adenocarcinoma and 0.76 (0.63-0.89) for SQCC. In pairs with discordant diagnoses (n = 7) the correct tumor type was identified with a similar frequency by biopsy (n = 4) and cytology (n = 3). Factors contributing to mistyping were poor differentiation, necrosis, low cellularity, and lack of supporting IHC. All concordant diagnoses for which verification was available (n = 57) were correct. IHC was used more frequently to subtype NSCLC in biopsy than cytology (32% versus 6%; p = 0.0001).
Conclusions: Small biopsy and cytology achieve comparable rates of definitive and accurate NSCLC subtyping, and the optimal results are attained when the two modalities are considered jointly. The lower requirement for IHC in cytology highlights the strength of cytomorphology in NSCLC subtyping. Whenever clinically feasible, obtaining parallel biopsy and cytology specimens is encouraged.
Similar articles
-
Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.J Thorac Oncol. 2010 Apr;5(4):442-7. doi: 10.1097/JTO.0b013e3181d40fac. J Thorac Oncol. 2010. PMID: 20195168
-
Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing.J Thorac Oncol. 2011 Mar;6(3):451-8. doi: 10.1097/JTO.0b013e31820517a3. J Thorac Oncol. 2011. PMID: 21266922
-
Napsin A/p40 antibody cocktail for subtyping non-small cell lung carcinoma on cytology and small biopsy specimens.Cancer Cytopathol. 2016 Jul;124(7):472-84. doi: 10.1002/cncy.21707. Epub 2016 Feb 29. Cancer Cytopathol. 2016. PMID: 27412420
-
[Non-small cell lung cancer. Subtyping and predictive molecular marker investigations in cytology].Pathologe. 2012 Jul;33(4):301-7. doi: 10.1007/s00292-012-1577-9. Pathologe. 2012. PMID: 22711372 Review. German.
-
Can cytology reliably subtype non-small cell lung carcinomas?Cytopathology. 2022 Jan;33(1):8-13. doi: 10.1111/cyt.13056. Epub 2021 Sep 21. Cytopathology. 2022. PMID: 34494327 Review.
Cited by
-
Promising targets and current clinical trials in metastatic squamous cell lung cancer.Front Oncol. 2014 Dec 9;4:320. doi: 10.3389/fonc.2014.00320. eCollection 2014. Front Oncol. 2014. PMID: 25538887 Free PMC article. Review.
-
Genetic Markers in Lung Cancer Diagnosis: A Review.Int J Mol Sci. 2020 Jun 27;21(13):4569. doi: 10.3390/ijms21134569. Int J Mol Sci. 2020. PMID: 32604993 Free PMC article. Review.
-
Immune-enrichment of non-small cell lung cancer baseline biopsies for multiplex profiling define prognostic immune checkpoint combinations for patient stratification.J Immunother Cancer. 2019 Mar 28;7(1):86. doi: 10.1186/s40425-019-0544-x. J Immunother Cancer. 2019. PMID: 30922393 Free PMC article.
-
Diagnostic patterns of non-small-cell lung cancer at Princess Margaret Cancer Centre.Curr Oncol. 2020 Oct;27(5):244-249. doi: 10.3747/co.27.5757. Epub 2020 Oct 1. Curr Oncol. 2020. PMID: 33173375 Free PMC article.
-
Utility of immunochemistry in cytology.J Cytol. 2016 Apr-Jun;33(2):71-5. doi: 10.4103/0970-9371.182520. J Cytol. 2016. PMID: 27279681 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous